首页|Ginsenoside Rk3 modulates gut microbiota and regulates immune response of group 3 innate lymphoid cells to against colorectal tumorigenesis

Ginsenoside Rk3 modulates gut microbiota and regulates immune response of group 3 innate lymphoid cells to against colorectal tumorigenesis

扫码查看
The gut microbiota plays a pivotal role in the immunomodulatory and protumorigenic microenviron-ment of colorectal cancer(CRC).However,the effect of ginsenoside Rk3(Rk3)on CRC and gut microbiota remains unclear.Therefore,the purpose of this study is to explore the potential effect of Rk3 on CRC from the perspective of gut microbiota and immune regulation.Our results reveal that treatment with Rk3 significantly suppresses the formation of colon tumors,repairs intestinal barrier damage,and regulates the gut microbiota imbalance caused by CRC,including enrichment of probiotics such as Akkermansia muciniphila and Barnesiella intestinihominis,and clearance of pathogenic Desulfovibrio.Subsequent metabolomics data demonstrate that Rk3 can modulate the metabolism of amino acids and bile acids,particularly by upregulating glutamine,which has the potential to regulate the immune response.Furthermore,we elucidate the regulatory effects of Rk3 on chemokines and inflammatory factors associated with group 3 innate lymphoid cells(ILC3s)and T helper 17(Th17)signaling pathways,which inhibits the hyperactivation of the Janus kinase-signal transducer and activator of transcription 3(JAK-STAT3)signaling pathway.These results indicate that Rk3 modulates gut microbiota,regulates ILC3s immune response,and inhibits the JAK-STAT3 signaling pathway to suppress the development of colon tumors.More importantly,the results of fecal microbiota transplantation suggest that the inhibitory effect of Rk3 on colon tumors and its regulation of ILC3 immune responses are mediated by the gut microbiota.In summary,these findings emphasize that Rk3 can be utilized as a regulator of the gut microbiota for the prevention and treatment of CRC.

Colorectal cancerGinsenosideImmune cellsGut microbiota

Xue Bai、Rongzhan Fu、Yannan Liu、Jianjun Deng、Qiang Fei、Zhiguang Duan、Chenhui Zhu、Daidi Fan

展开 >

Shaanxi Key Laboratory of Degradable Biomedical Materials,School of Chemical Engineering,Northwest University,Xi'an,710069,China

Biotech & Biomed Research Institute,Northwest University,Xi'an,710069,China

School of Chemical Engineering and Technology,Xi'an Jiaotong University,Xi'an,710069,China

国家重点研发计划国家重点研发计划国家自然科学基金国家自然科学基金Natural Science Basic Research Program of Shaanxi,China

2021YFC21015002021YFC210390022278335219782362023-JC-JQ-17

2024

药物分析学报(英文)
西安交通大学

药物分析学报(英文)

影响因子:0.244
ISSN:2095-1779
年,卷(期):2024.14(2)
  • 1
  • 52